Alnylam's Vutrisiran Shows Promise for ATTR Amyloidosis at European Cardiology Congress

Aug 30, 2024, 10:04 AM

Alnylam Pharmaceuticals presented detailed results from the HELIOS-B Phase 3 study of its drug Vutrisiran, also known as Amvuttra, at the European Society of Cardiology Congress. The study focused on patients with ATTR amyloidosis with cardiomyopathy. The results showed a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events. Additionally, there were 31% and 36% reductions in all-cause mortality during the 33-36-month double-blind period and up to month 42, respectively. Despite these positive outcomes, some endpoints, including monotherapy mortality and combination with tafamidis, were not statistically significant. Alnylam believes Amvuttra could be a first-line therapy for ATTR cardiomyopathy, though it might be more likely used as an add-on to Pfizer's Vyndamax/Vyndaqel. The company's stock, $ALNY, experienced a 2% decline, while competitor BridgeBio's stock, $BBIO, rose by 9%. The full study data supports the drug's benefit but leaves doctors with tough choices.